Bitcoin ZK Rollup project Citrea launches token CTR
Foresight News reports, according to The Block, the Bitcoin ZK Rollup project Citrea has launched the CTR token. The total supply of CTR is capped at 10 billion tokens, with 60% allocated to the community. This includes 12% distributed as initial shares during the genesis airdrop, 25.16% into the treasury managed by xCTR, and 22.83% designated for ecosystem development. The remaining 40% consists of 19.35% allocated to investors and 20.66% to early contributors. These tokens will be locked and released gradually after 4 years.
Citrea also introduces a dual treasury system, where the Citrea governance treasury is directly controlled by xCTR holders, who will vote on liquidity incentives, council and infrastructure providers, and payments. The independent Citrea Foundation treasury will be responsible for research and development, ecosystem funding, operations, and strategic initiatives.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Terranor Group schedules Q3 results presentation
WTI crude oil futures prices fall by more than 1%
Yen appreciation and global bond slump lead Japan GPIF to first loss in six quarters, with almost no asset allocation adjustment
According to the latest quarterly report from Japan’s Government Pension Investment Fund (GPIF), its asset allocation remained almost unchanged from its model portfolio for the three months ending in late September. However, the fund recorded a 1.7% quarterly loss during this period—the first loss in six quarters—due to a global slump in bond prices and the appreciation of the yen.
GlaxoSmithKline endorses: anti-inflammatory biotech company Rezera (RZRA.US) plans to raise $200 millions through IPO, with a valuation of $254 millions
Rezera plans to raise $200 million in its IPO on Nasdaq, with an offering price between $11 and $13. GSK intends to subscribe for up to $25 million. The mid-point valuation is $254 million, and the company focuses on oral NLRP3 inhibitors.
Crypto prices
More
